Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Tyrosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 3/20 | 0.68 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.62 |
| ▸ | ADORA3 known ✓ | P0DMS8 | 1/20 | 0.62 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.62 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.62 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.54 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.54 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.54 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.54 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.54 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.54 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.54 |
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.54 |
| ▸ | GRIA2 known ✓ | P42262 | 1/20 | 0.54 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.96 |
| ▸ | ALPI | P09923 | 1/20 | 0.68 |
| ▸ | PKM | P14618 | 1/20 | 0.68 |
| ▸ | XIAP | P98170 | 1/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tyrosine SCHEMBL26981408 | 1.00 | SLC7A5 (0.96) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL5072275 | 1.00 | SLC7A5 (0.96) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL8682743 | 1.00 | SLC7A5 (0.96) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL8682745 | 1.00 | SLC7A5 (0.96) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL21294157 | 0.98 | SLC7A5 (0.92) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL22393326 | 0.98 | SLC7A5 (0.92) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL11195244 | 0.98 | SLC7A5 (0.92) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL22322372 | 0.98 | SLC7A5 (0.92) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL21410211 | 0.98 | SLC7A5 (0.92) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL28957146 | 0.98 | SLC7A5 (0.92) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3507371-B1 | COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | UNIV RUTGERS (US) | 2026-01-28 | — | — | EP | disclosed |
| WO-2024112083-A1 | PYRIMIDOPYRIMIDINONE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 엑세쏘바이오파마 | 2024-05-30 | — | — | WO | disclosed |
| US-20230174613-A1 | METHODS AND COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2023-06-08 | — | — | US | disclosed |
| CN-115697386-A | Method and medicine for treating Parkinson's disease | 泰伦基国际有限公司 | 2023-02-03 | — | — | CN | disclosed |
| US-11542315-B2 | Methods and compositions for treating diseases and disorders of the nervous system | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-01-03 | — | — | US | disclosed |
| US-20200397812-A1 | INHIBITORS OF HUMAN EZH2, AND METHODS OF USE THEREOF | Epizyme, Inc. | 2020-12-24 | — | — | US | disclosed |
| EP-3507371-A1 | METHODS AND COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | Rutgers, The State University of New Jersey (US) | 2019-07-10 | — | — | EP | disclosed |
| US-20190194287-A1 | METHODS AND COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2019-06-27 | — | — | US | disclosed |
| US-20180355305-A1 | DEEP EUTECTIC SOLVENTS AND/OR IONIC LIQUIDS AS FEED MEDIA | MERCK PATENT GMBH (DE) | 2018-12-13 | — | — | US | disclosed |
| CN-105616327-B | A kind of sea cucumber boiling liquid extract and the preparation method and application thereof | 大连工业大学 | 2018-11-13 | — | — | CN | disclosed |
| EP-2614369-A2 | INHIBITORS OF HUMAN EZH2, AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2013-07-17 | — | — | EP | disclosed |
| US-20120071418-A1 | Inhibitors of Human EZH2 and Methods of Use Thereof | Epizyme, Inc. (US) | 2012-03-22 | — | — | US | disclosed |
| WO-2012034132-A2 | INHIBITORS OF HUMAN EZH2, AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2012-03-15 | — | — | WO | disclosed |
| CN-101310007-A | Method for augmenting nucleated cells (expansion) and transplanting (engulfing) from cord blood using stromal cells from cord blood | UNIV JOHNS HOPKINS (US) | 2008-11-19 | — | — | CN | disclosed |
| EP-1913366-A2 | GRATING-BASED SENSOR COMBINING LABEL-FREE BINDING DETECTION AND FLUORESCENCE AMPLIFICATION AND READOUT SYSTEM FOR SENSOR | SRU Biosystems, Inc. (US) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007019024-A2 | GRATING-BASED SENSOR COMBINING LABEL-FREE BINDING DETECTION AND FLUORESCENCE AMPLIFICATION AND READOUT SYSTEM FOR SENSOR | SRU BIOSYSTEMS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20060177446-A1 | Polypeptides that bind an anti-tissue factor antibody and uses thereof | GENENTECH, INC. (US) | 2006-08-10 | — | — | US | disclosed |
| EP-1629014-A2 | POLYPEPTIDES THAT BIND AN ANTI-TISSUE FACTOR ANTIBODY AND USES THEREOF | Genentech, Inc. (US) | 2006-03-01 | — | — | EP | disclosed |
| WO-2005000896-A2 | POLYPEPTIDES THAT BIND AN ANTI-TISSUE FACTOR ANTIBODY AND USES THEREOF | GENENTECH, INC. (US) | 2005-01-06 | — | — | WO | disclosed |
| US-4725645-A | USING A TRIALKYLCYANOSILANE | SOLVAY & CIE. (SOCIETE ANONYME) (BE) | 1988-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200397812-A1 | INHIBITORS OF HUMAN EZH2, AND METHODS OF USE THEREOF | EZH2, DOT1L, PRDM7 | PTGS1 4546/4885EGFR 2273/4885ADORA3 4728/4885 |
| US-20120071418-A1 | Inhibitors of Human EZH2 and Methods of Use Thereof | EZH2, DOT1L, PRDM7 | PTGS1 4468/4885EGFR 2328/4885ADORA3 4743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.